# Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma

Source: https://onco.cc/trials/nct06854445/  
OnCo record `nct06854445` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Gemcitabine, Oxaliplatin and TQB2825 in non-Hodgkin lymphoma, run by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd., now recruiting.

## Summary

Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma is a phase 2 interventional study registered as NCT06854445 by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd., with 55 participants planned, started 2025-03-12 and due to reach its primary completion in 2025-10. Interventions recorded: TQB2825 Injection + Gemcitabine Hydrochloride for Injection + Oxaliplatin for Injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06854445
- Phase: 2
- Setting: Phase II Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
- Enrolled: 55

## Sources

- ClinicalTrials.gov NCT06854445: https://clinicaltrials.gov/study/NCT06854445

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Oxaliplatin](https://onco.cc/drugs/oxaliplatin/), [TQB2825](https://onco.cc/drugs/tqb2825/)

---
JSON: https://onco.cc/api/v1/entities/nct06854445.json